RNA
Atrium Therapeutics, Inc. Common Stock
$13.20
-2.08%
2026-08-21
About Atrium Therapeutics, Inc. Common Stock
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.
Key Fundamentals
Forward P/E
-1.59
EPS (TTM)
$-5.44
ROE
-44.0%
Revenue Growth (YoY)
-21.9%
Profit Margin
-184.1%
Debt/Equity
0.78
Price/Book
0.94
Beta
0.93
Market Cap
$219.6M
Avg Volume (10D)
128K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$14.14
60D Low
$11.13
Avg Volume
190K
Latest Close
$13.20
Get breakout alerts for RNA
Sign up for Breakout Scanner to receive daily notifications when RNA triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
Atrium Therapeutics, Inc. Common Stock (RNA) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors RNA daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. RNA operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.